Kenichi Ikejima

Kenichi Ikejima

Auto-generated profile, based on publicly available information

Kenichi Ikejima

Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2009 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
TMTomokazu Mizui
Tomokazu Mizui
SYShunhei Yamashina
Shunhei Yamashina
ITIsei Tanida
Isei Tanida
YTYoshiyuki Takei
Yoshiyuki Takei
TUTakashi Ueno
Takashi Ueno
SWSumio Watanabe
Sumio Watanabe

29 November 2011 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
YIYuki Igusa
Yuki Igusa
SYShunhei Yamashina
Shunhei Yamashina
KIKousuke Izumi
Kousuke Izumi
YIYoshihiro Inami
Yoshihiro Inami
HFHiroo Fukada
Hiroo Fukada
SWSumio Watanabe
Sumio Watanabe

1 June 2001 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
NENobuyuki Enomoto
Nobuyuki Enomoto
KIKenichi Ikejima
Kenichi Ikejima
SYShunhei Yamashina
Shunhei Yamashina
MHMiyoko Hirose
Miyoko Hirose
HSHidetake Shimizu
Hidetake Shimizu
RTRonald G. Thurman
Ronald G. Thurman

1 May 2001 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
NSNobuhiro Sato
Nobuhiro Sato
KLKai O. Lindros
Kai O. Lindros
EBEnrique Baraona
Enrique Baraona
KIKenichi Ikejima
Kenichi Ikejima
EMEsteban Mezey
Esteban Mezey
VRVijay A. Ramchandani
Vijay A. Ramchandani

27 April 2009 in Hepatology
Verified
Journal Article
Open access
PDF file
TATomonori Aoyama
Tomonori Aoyama
KIKenichi Ikejima
Kenichi Ikejima
KKKazuyoshi Kon
Kazuyoshi Kon
KOKyoko Okumura
Kyoko Okumura
KAKumiko Arai
Kumiko Arai
SWSumio Watanabe
Sumio Watanabe
Pathogenesis of metabolic syndrome–related nonalcoholic steatohepatitis (NASH) involves abnormal tissue-repairing responses in the liver. We investigated the effect of pioglitazone, a thiazolidinedione derivative (TZD), on hepatic regenerative responses in obese, diabetic KK-Ay mice. Male KK-Ay mice 9 weeks after birth underwent two-thirds partial hepatectomy (PH) after repeated intragastric injections of pioglitazone (25 mg/kg) for 5 days. Almost half of the KK-Ay mice died within 48 hours of PH;however, mortality was completely prevented in mice pretreated with pioglitazone. In KK-Ay mice, bromodeoxyuridine (BrdU) incorporation to hepatocyte nuclei 48 hours after PH reached only 1%; however, pioglitazone pretreatment significantly increased BrdU-positive cells to 8%. Cyclin D1 was barely detectable in KK-Ay mice within 48 hours after PH. In contrast, overt expression of cyclin D1 was observed 24 hours after PH in KK-Ay mice pretreated with pioglitazone. Hepatic tumor necrosis factor alpha (TNF-α) messenger RNA (mRNA) was tremendously increased 1 hour after PH in KK-Ay mice, the levels reaching ninefold over C57Bl/6 given PH, whereas pioglitazone blunted this increase by almost three-fourths. Pioglitazone normalized hypoadiponectinemia in KK-Ay mice almost completely. Serum interleukin (IL)-6 and leptin levels were elevated extensively 24 hours after PH in KK-Ay mice, whereas the levels were largely decreased in KK-Ay mice given pioglitazone. Indeed, pioglitazone prevented aberrant increases in signal transducers and activators of transcription (STAT)3 phosphorylation and suppressor of cytokine signaling (SOCS)-3 mRNA in the liver in KK-Ay mice. Conclusion: These findings indicated that pioglitazone improved hepatic regeneration failure in KK-Ay mice. The mechanism underlying the effect of pioglitazone on regeneration failure most likely involves normalization of expression pattern of adipokines and subsequent cytokine responses during the early stage of PH. (Hepatology 2009.)

1 October 2020 in Clinical and Molecular Hepatology
Verified
Journal Article
Open access
PDF file
KIKenichi Ikejima
Kenichi Ikejima
KKKazuyoshi Kon
Kazuyoshi Kon
SYShunhei Yamashina
Shunhei Yamashina
Two major causes of steatohepatitis are alcohol and metabolic syndrome. Although the underlying causes of alcoholrelated liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) differ, there are certain similarities in terms of the mode of disease progression and underlying pathophysiological mechanisms. Further, excessive alcohol consumption is often seen in patients with metabolic syndrome, and alcoholic hepatitis exacerbation by comorbidity with metabolic syndrome is an emerging clinical problem. There are certain ethnic differences in the development of both NAFLD and ALD. Especially, Asian populations tend to be more susceptible to NAFLD, and genetic polymorphisms in patatin-like phospholipase domain-containing 3 (PNPLA3) play a key role in both NAFLD and ALD. From the viewpoint of pathophysiology, cellular stress responses, including autophagy and endoplasmic reticulum (ER) stress, are involved in the development of cellular injury in steatohepatitis. Further, gutderived bacterial products and innate immune responses in the liver most likely play a profound role in the pathogenesis of both ALD and NASH. Though the recent progress in the treatment of viral hepatitis has reduced the prevalence of viral-related development of hepatocellular carcinoma (HCC), non-viral HCC is increasing. Alcohol and metabolic syndrome synergistically exacerbate progression of steatohepatitis, resulting in carcinogenesis. The gut-liver axis is a potential therapeutic and prophylactic target for steatohepatitis and subsequent carcinogenesis.